Eco Animal Health - ECOVAXXIN® MS EU authorisation paves way for commercial launch
Eco Animal Health reports that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a Positive Opinion recommending the granting of EU marketing authorisation for ECOVAXXIN® MS, the EAH vaccine against Mycoplasma synoviae in poultry. The authorisation represents a significant step towards commercialisation.CEO David Hallas commented: "We are delighted to have received a Positive Opinion from the CVMP for ECOVAXXIN MS …This marks an exciting time for the Company, with further submissions expected over the next 12 months for additional products from our R&D pipeline, underpinning ECO's next phase of growth."
Eco Animal Health expects the EMA to issue a marketing authorisation during the first quarter of 2026, so that the Group anticipates making ECOVAXXIN® MS commercially available in the European Union in the second half of 2026 (as expected and outlined in FY25 results). EAH submitted its Market Authorisation Application (MAA) for ECOVAXXIN® MS on 3 March 2025. During the coming 12 months we expect the Group to submit marketing authorisation requests for ECOVAXXIN® MS in additional geographies and make further submissions for vaccine products in its R&D pipeline, with eight projects prominent.
Our Fair Value remains 136p per share, indicative of 7.8x FY27E EV/EBITDA (3.4x currently).
Eco Animal Health Group is engaged in the manufacture and supply of animal health products. Co.'s activities were conducted through a network including both regional offices, (notably in Shanghai and Princeton) and overseas subsidiaries. Co.'s patented molecule, Aivlosin® is used for the treatment of pigs and poultry diseases and is prescribed under veterinary control for the short duration treatment of diagnosed diseases. Co.'s products also include Ecomectin, an endectocide that controls worms, ticks, lice and mange in grazing stock and pigs.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.